Summit Therapeutics - ADR Financials

$17.55

$0.55 (3.24%)

As on 11-Sep-2026 16:24EDT

Market cap

$14,044 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

17.9

Div. Yield

0 %

Annual
Quarterly

Income Statement (£ Mln)	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Operating Revenue	--	--	--	--	--	0.70
Cost of Revenue	0.05	0.11	15.01	2.05	2.05	2.51
Gross Profit	-0.05	-0.11	-15.01	-2.05	-2.05	-1.81
Operating Expenses	874.79	1,094.37	180.51	87.69	478.23	64.28
Operating Profit (EBIT)	-874.79	-1,094.37	-180.51	-89.74	-478.23	-72.09
Other Income	--	--	--	--	--	--
Profit before Tax	-856.04	-1,079.54	-176.77	-615.87	-482.37	-78.78
Provision for Tax	--	--	-0.31	-0.95	-0.95	-4.40
Profit after Tax (Net Income)	-856.09	-1,079.59	-176.77	-614.93	-482.37	-74.38
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	-78.78

Liabilities (£ Mln)	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Shareholder's Funds	629.98	488.98	310.64	77.69	61.48	126.65
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	18.64	14.35	4.06	104.85	82.98	498.73
Current Liabilities	103.57	54.17	33.35	20.41	16.15	38.78
Total Liabilities	855.75	557.50	348.05	202.95	160.60	664.17

Assets (£ Mln)	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Non-Current Assets	31.61	22.92	9.44	13.24	10.48	7.46
Current Assets	720.58	534.58	338.61	189.71	150.13	656.71
Total Assets	855.75	557.50	348.05	202.95	160.60	664.17
Total Debt*	20.38	15.50	5.77	106.10	83.96	518.76
Net Current Assets	617.01	647.31	382.02	169.31	169.31	617.93

Cashflow (£ Mln)	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Cash From Operating Activities	--	-239.67	-113.56	-76.76	-60.74	-41.58
Cash Flow from Investing Activities	--	-129.37	-164.09	--	-465.14	-0.62
Cash from Financing Activities	--	458.31	304.63	86.51	68.46	620.24
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Adjusted EPS (£)	-1.12	-1.41	-0.24	--	-0.69	--
Cash EPS (£)	--	-1.41	-0.24	--	-0.69	--
Adjusted Book Value (£)	--	0.64	0.42	--	0.09	--
Dividend per Share (£)	--	--	--	--	--	--
Cash Flow per Share (£)	--	-0.31	-0.15	--	-0.09	--
Free Cash Flow per Share (£)	--	-0.31	-0.15	--	-0.09	--

Profitability Ratios	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
ROCE (%)	--	-263.03	-70.68	-148.32	-121.99	-20.34
ROE (%)	-153.01	-270.02	-91.04	-601.85	-512.79	-70.86
ROA (%)	-173.90	-238.44	-64.16	-141.83	-116.97	-19.13
EBIT Margin (%)	--	--	--	--	--	-10,235.63
Net Margin (%)	--	--	--	--	--	-10,561.06
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Revenue Growth (%)	--	--	--	-1.00	-1.00	-0.61
EBIT Growth (%)	-10.72	-540.58	-142.11	-24.48	-32.26	16.36
Net Profit Growth (%)	-130.47	-510.72	63.35	-726.73	-640.17	13.66
EPS Growth (%)	-122.88	-4.88	0.65	--	-1.90	--
Book Value Growth (%)	321.10	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Debt to Equity	--	0.03	0.02	1.37	1.37	4.10
Short term debt to equity ratio	0.01	0.01	0.01	0.04	0.04	0.17
Current Ratio	6.96	9.87	10.15	9.30	9.30	16.93
Quick Ratio	6.96	--	--	9.18	9.15	9.16
Interest Coverage	--	--	-19.40	-5.45	-4.23	-16.38

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Jan-24	Dec-23	Jan-23	Dec-22	Jan-22	Dec-21	Jan-21	Dec-20
Debtors to sales (%)	--	--	--	--	--	868.24
Asset Turnover	--	--	--	--	--	0.00
Receivable days	--	--	--	--	--	6,034.99
Inventory Days	--	--	59.41	27,077.05	27,077.05	22,422.41
Payable days	--	31,626.28	77.54	269.22	219.64	343.53
Cash Conversion Cycle	--	--	--	--	--	28,113.87

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.